Evercore ISI Group downgraded Tenax Therapeutics Inc (TENX) to In-Line from Outperform on August 11, 2026.
The past 90 days include five active firms, with one rating the stock bullish. The consensus price targets from 10 analysts as of October 30, 2026, have a mean of $9.82, a median of $5.10 and a range of $4.04 to $36.75.
For Q4 FY2026, analysts expect EPS of -$0.36 and revenue of $0. The next earnings report is scheduled for March 8, 2027.
